chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient woke up early 2/19/2020 due to symptoms: headache, pain to right arm, body felt very warm, unable to lift right arm and very tender to touch.  Patient had received Men B vaccine the day before, 2/18/2020.
Right upper arm very swollen, reddened and hot to touch. Pt placed on Cefzil 250mg/5mL, 1 tsp every 12 hours for 10 days.
After the 1st vaccine - Right arm - I felt fine.  My arm became very sore and I had a large red ring around the injection spot for 2.5 weeks. It was still a bit sore so I opted for the left arm for shot 2. The next shot - the 2nd shot I felt fine with a sore arm once again. This time the soreness was much more acute. Painful and hard to lift my left arm all day.  Not to bad until around 8:00 pm. I started feel very tired with the chills. I went to bed around 9:00 and woke in the night with a high temperature, clothing soaked in sweat so changed. I took Tylenol and went back to bed with the chills. Morning woke up to  soaked clothing  once again. The chilles, head ache and the feeling a truck just ran over me.  I have a puppy so at lunch I sat outside in the sun with two down coats on.  Felt tired, like I had the flu - no appetite, tired, headache, joints sore.  Went to bed and the next morning -Saturday morning I felt fine.  Arm still sore but no flu like symptoms at all.   Therefore with some patience they may go through what I did but it works it way through after two days.  Adding to this I am a very healthy 63 year old.
Arm pain and numbness on arm of injection site (left), described as tingling and radiating pain.
Soreness at injection site; injection site become raised; Tiredness; shoulder pain; left side of neck felt stiff; bruise at injection site; injection site  become white; injection site numb to touch; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0178) via an unspecified route of administration in the left arm on 29May2021 at 11:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included ankylosis spondylitis. The patient previously took Gluten and experienced allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included sulfasalazine (MANUFACTURER UNKNOWN), naproxen sodium (ALEVE), sulindac (MANUFACTURER UNKNOWN), zingiber officinale (GINGER) and iron (MANUFACTURER UNKNOWN); all from an unknown date for  unknown indications and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29May2021, the patient experienced soreness at injection site, later in the day injection site became raised and white and numb to touch. On 29May2021, 7 hours after injection, the patient had tiredness and shoulder pain (felt like it needed to pop, could not lie on it). On 29May2021, the patient experienced left side of neck stiff (woke up in the middle of the night because of pain) and bruise at injection site. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events.   Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events of soreness at injection site, injection site become raised and white and numb to touch, tiredness, shoulder pain, neck stiff and bruise at injection site was recovered on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Cellulitis; Weakness during walk; Hot and warm at site; This spontaneous case was reported by an other health care professional and describes the occurrence of INJECTION SITE CELLULITIS (Cellulitis), ASTHENIA (Weakness during walk) and INJECTION SITE WARMTH (Hot and warm at site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INJECTION SITE CELLULITIS (Cellulitis), ASTHENIA (Weakness during walk) and INJECTION SITE WARMTH (Hot and warm at site). At the time of the report, INJECTION SITE CELLULITIS (Cellulitis), ASTHENIA (Weakness during walk) and INJECTION SITE WARMTH (Hot and warm at site) was resolving.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was withdrawn on an unknown date.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment information provided.
Info has been received from a licensed practical nurse (LPN) concerning a 56 year old female with an allergy to sulfa and quinine sulfate (QUINAMM), hypertension, vascular (circulatory) insufficiency and stasis dermatitis who on 10/15/2002 was vaccinated IM in the left deltoid with a dose of pneumococcal vaccine 23 polyvalent (lot #643783/0709M). Concomitant therapy included metoclopramide hydrochloride (REGLAN), cetirizine hydrochloride (ZYRTEC), esomeprazole magnesium (NEXIUM), furosemide (LASIX), verepamil, irbesartan (AVAPRO), ibuprofen (MOTRIN), diltiazem hydrochloride (CARDIZEM CD), iron (unspecified) and estrogens, conjugated (+) medroxyprogesterone acetate (PREMPRO). On 10/15/2002 a few hours after administration of the vaccine, the pt developed erythema, soreness, swelling and pain around the injection site. The LPN also reported that movement of the pt's deltoid was described to be painful and limited. In follow-up, the LPN reported that the pt developed redness and swelling in the left upper arm, nausea and slight diarrhea. The pt's intervention treatment included methylprednisolone acetate (DEPO-MEDROL), promethazine HCl (PHENERGAN), and a "Pred-Pak". In follow-up, the LPN reported that the pt was treated with methylprednisolone acetate (DEPO-MEDROL), 80 mg IM, and was told to put ice on the arm. The outcome of the pt's events was unknown. The reporter expressed a concern regarding the lot number. No additional info is expected. The records of testing prior to release of this lot have been checked by Compliance and found to be satisfactory. The lot complies with the standards of the Center for Biologics Evaluation and Research and was released.
This spontaneous report as received from a medical assistant refers to a 6 month old patient of unknown gender. On an unknown date in approximately November 2012, at the age of 2 months, the patient was vaccinated with the first dose of PEDVAXHIB (dose, route and lot number not reported). The patient received the second dose of PEDVAXHIB (dose, route and lot number not reported) on an unknown date in approximately January 2013, at the age of 4 months. The patient received the third dose of PEDVAXHIB (dose, route and lot number not reported) on an unknown date in approximately March 2013, at the age of 6 months. On 06-DEC-2013, at the age of 15 months the patient received the fourth dose of PEDVAXHIB (dose, route and lot number not reported). No adverse events were reported. This is one of two reports received from the same source (linked MARRS#: 1312USA006089). Additional information has been requested.
Patient became weak within 24 hours and declined daily until she died on 4/5/21. Family wanted no intervention except comfort care given patient's wishes.
Headaches; Fever; A red , big and hot circle of 2 inches of diameter at the injection site; swelling at injection; A red , big and hot circle of 2 inches of diameter at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (A red , big and hot circle of 2 inches of diameter at the injection site), HEADACHE (Headaches), PYREXIA (Fever), VACCINATION SITE ERYTHEMA (A red , big and hot circle of 2 inches of diameter at the injection site) and VACCINATION SITE SWELLING (swelling at injection) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE WARMTH (A red , big and hot circle of 2 inches of diameter at the injection site), HEADACHE (Headaches), PYREXIA (Fever), VACCINATION SITE ERYTHEMA (A red , big and hot circle of 2 inches of diameter at the injection site) and VACCINATION SITE SWELLING (swelling at injection). At the time of the report, VACCINATION SITE WARMTH (A red , big and hot circle of 2 inches of diameter at the injection site), HEADACHE (Headaches), PYREXIA (Fever), VACCINATION SITE ERYTHEMA (A red , big and hot circle of 2 inches of diameter at the injection site) and VACCINATION SITE SWELLING (swelling at injection) outcome was unknown.            No concomitant and treatment medication provided   This case was linked to MOD-2021-020277 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 19-Jun-2021: Follow up received on 19-Jun-2021. No new information On 30-Jun-2021: Follow up received on 30-jun-2021. No new information
Patient presented with a raised red rash on the back of her upper arm that migrated down to the outer elbow.
Information has been received from a physician referring to a patient of unknown age and gender. The patient's concomitant medication, medical history and drug reactions/allergies were not reported. On 09-NOV-2015, the patient was vaccinated with PROQUAD (lot # L027634 with expiration date 21-JAN-2017, dose and route were not reported) for prophylaxis. On 14-NOV-2015, the patient received FLUMIST, which is sooner than the recommended 28 day waiting period for the concomitant administration of live vaccines, if not given simultaneously (product use issue). No adverse effects were reported. Additional information has been requested.
I was given the vaccine Monday and upon returning to work on Tuesday I was extremely ill and shaking to the point I collapsed into a seizure that lasted for 15 minutes. I was administered 6mg of Lorazepam within that 15 Min and to no avail of slowing my seizure. I was taken by ambulance to the Emergency Room at hospital and given a CT and a drug test (I requested the drug test upon arrival for work). It was determined the Covid vaccine did not mix well with my prescribed medication of Prozac 30 mg. I slept for two solid days without even knowing I was home beginning Tuesday night through Thursday morning. I was left severely foggy upon returning to work the same Thursday that same week. I was fortunate I was not left with severe deficits due to the length of the seizure. I have waited to report in order to document if symptoms persisted, how long, types and severity, etc.  I experienced frequent brain fog and memory loss in the middle of an action, with no regard to what the action may be. Driving and forgetting where I am headed, speaking and forgetting often what I am meaning  to say - "can't find the word" - several times through single sentences and even forgetting completely what is being discussed as I am speaking.
Booster vaccine selected for administration was past its 10-week manufacturer refrigeration period (8/18/23). Patient has been contacted (8/19/23) and is making plans for re-vaccination with Moderna to ensure full booster protection. No adverse reactions or symptoms reported.
Information has been received from a physician concerning a 30 year old male who was vaccinated with varicella vaccine. Subsequently, within one week, the pt experienced "uro-genital pox-like rash." The physician stated that the pt had a "small number of lesions and it does not look like simplex." Unspecified medical attention was sought. Additional info has been requested.
This spontaneous report as received from a pharmacy student refers to an unspecified number of patients. On an unknown date the patients were vaccinated with doses of M-M-R II (dose, route and indication not reported) separately. Pharmacy student stated an unspecified number of patients may have received M-M-R II that was transported via pneumatic tube system for an unspecified time in the past. Pharmacy student stated pneumatic tube system used to transport vaccines, namely M-M-R II, when urgent and the duration of transit is less than 30 minutes. Pharmacy student stated no further specific time and temperature conditions at time of call. No adverse effects reported. Additional information has been requested.
When I woke on the 19th I was trying read my bible and I couldn't concentrate and I was really cold. I went to back to bed and slept most of the day. I was really cold and fatigued and didn't have an appetite. I took some Tylenol. I woke up about 3:30 AM Saturday and my back, arms and my head were all hurting and I took some Tylenol and went back to bed. I woke up about 6AM and was covered in sweat.  I didn't want to do anything Saturday, I rested most of Saturday and Sunday. Today the 22nd I am back to my normal self.
This report from study was reported via Pregnancy Registry (initial receipt 19-Jul-2014), concerns a neonate patient. The concomitant medications received by the patient from the mother in-utero included prenatal vitamins, folic acid, docosahexanoic acid, ergocalciferol, ascorbic acid, azathioprine, amoxicillin, diphenhydramine, paracetamol and Tdap vaccine. The mother had a medical history of depression, anorexia (resolved in 2013) and Ulcerative Colitis. On 10-Oct-2013, the patient received AFLURIA (batch number not reported) via the mother in-utero, who received the vaccine. On 10-Feb-2014 and 31-May-2014, the patient's mother underwent an ultrasound scan which showed that the patient's kidney was dilated. The patient was born at week 40 of gestation (birth weight: 3632.0 grams, Apgars at 1 min: 9, Apgars at 5 min: 9). On 14-Jul-2014, the patient was diagnosed with grade 2 hydronephrosis. The patient was prescribed prophylactic amoxicillin (1.4 ml of 125 mg/ml solution QD) to prevent urinary tract infection. The Urologist would follow-up with the child in 6 weeks but doesn't think a surgery will be required. Outcome was not reported. Reporter's comments: The reporter assessed the event as serious as it was a congenital anomaly.
Resident on palliative/comfort care services since readmission to facility on 2/9/2021. Received first dose of Moderna COVID-19 vaccine on 1/7/2021. Received second dose of Moderna COVID-19 vaccine on 3/8/21. G-tube feeding discontinued on 2/14/21. Resident expired 3/10/2021.
Dizziness,  muscle aches and soreness,  random muscle pain in wrist, jaw, lower back, neck. Had to use rescue inhaler once(normally only use before exercise) fatigue Brain Fog
Patient mentioned feeling very fatigued the day after receiving the shot(s), Moderna knocked patient on the butt, each dose/Adverse effect; This spontaneous case was reported by a non-health professional and describes the occurrence of FATIGUE (Patient mentioned feeling very fatigued the day after receiving the shot(s), Moderna knocked patient on the butt, each dose/Adverse effect) in a male patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     It was unknown if the patient had any allergies to vaccines, medications, food, and other products.     On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced FATIGUE (Patient mentioned feeling very fatigued the day after receiving the shot(s), Moderna knocked patient on the butt, each dose/Adverse effect). At the time of the report, FATIGUE (Patient mentioned feeling very fatigued the day after receiving the shot(s), Moderna knocked patient on the butt, each dose/Adverse effect) had resolved.            No concomitant medication information was provided.  It was reported that the patient could not recall the dates of vaccination/booster dose received. The fatigue did subside and the patient noted no other reactions or adverse events (skin, respiratory, etc.) associated with the shots. The event did not cause the patient to seek medical care.  No treatment medication information was provided.
Erythema- started about 2-3 days after vaccine administration. Area is 6 inches in length and 5.5 inches in width.
Pt had swollen arm from shoulder to elbow (right arm). Warm to touch, firm and painful, pt is warm to touch, not red.
I had taken the Moderna Bivalent Vaccine 07Dec2022. I was diagnosed with Covid on 15Dec2022; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (I had taken the Moderna Bivalent Vaccine 07Dec2022. I was diagnosed with Covid on 15Dec2022) in an elderly patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 014H22A) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: PFIZER BIONTECH COVID-19 VACCINE. Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 15-Dec-2022, the patient experienced COVID-19 (I had taken the Moderna Bivalent Vaccine 07Dec2022. I was diagnosed with Covid on 15Dec2022). At the time of the report, COVID-19 (I had taken the Moderna Bivalent Vaccine 07Dec2022. I was diagnosed with Covid on 15Dec2022) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Dec-2022, SARS-CoV-2 test: Positive.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was reported. No treatment medication information was reported.
Received the Hepatitis A, SHINGRIX and PNEUMOVAX all at the same time in the left deltoid at 9:30 AM on 5/3/18. In the evening on 5/3/2018 there was redness, swelling, warmth and pain in the left arm at the injection site. On 5/4/2018 symptoms included fatigue, oral temperature of 100.8 and increased pain, warmth, redness and swelling extending from the left deltoid area to the middle of the left forearm. Left arm was sensitive to touch. Symptoms continued on 5/7/18 and my skin was also sensitive to touch from left arm extending across my back over to right arm. On 5/9/18 symptoms: increased fatigue, chills, and just wanted to sleep. Increased sensitivity of skin of my arms and back to touch and to the fabric of my shirt and mild confusion. On 5/10/18 at 8:00am, I had chills, skin sensitivity, increased confusion/decreased mental status, unable to stand up and tremors. 911 was called and when the firemen were helping me down the stairs, I had a tonic/clonic seizure lasting 3-4 minutes. I was transported to the Emergency room for testing then later that afternoon admitted to the telemetry floor. My temperature was 39.8 degrees Celsius. I was given IV antibiotics/antiviral medication, DILANTIN and IV fluids. I was unconscious from 5/10/18 through 5/11/18. On 5/12/18, I started responding to questions but had significant memory loss. I was discharged home from the Hospital on 5/13/2018 with a diagnosis of viral encephalitis to take oral Valacyclovir three times a day until 6/3/18, and a diagnosis of new onset seizure related to the infection. As of 6/3/18, I still have some memory loss and difficulty recalling certain words, weight loss and my strength and appetite are not back to normal.
pt recv vax;admitted to hosp w/ bacterial meningitis on 24dec95;causative organism haemophilus influenza;B- lactose produced (CSF culture pn 24dec95)
25 mg Benadryl was administered post-injection when patient reported ?tight throat? and a cough, as well as redness at injection site. They have a history of allergies. Vitals at 10:45 am were 99% o2 sat, 105 pulse, 20 resp rate, 153/97 bp. At 11 am, symptoms had subsided. Vitals at this time were pulse 86, o2 sat 99%. Patient observed for 30 mins and cleared to leave per lead RN. VAERS filed.
as a single dose for covid-19 immunisation. Patient had no medical history and no past drug. At pharmacy or drug store the most recent COVID-19 vaccine was administered. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No other medications the patient received within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 20Apr2021 at 09:00 the second day of the first dose, she started with diarrhea, a little chest pressure. Patient did not receive any treatment for events. The events assessed as nonserious with outcome of not recovered.  No follow-up attempts are needed. No further information is expected.
Pt presented to clinic to report "tachycardia" and that her heart "lightens or eases" a little which makes her choke. Gets relief when she coughs. She received her vaccines at another facility but came here to report adverse effect. Advised her to see a physician asap. She has attempted to do so but has been unable to reach anyone to schedule. Provided her with phone numbers and addresses to two safety net providers.
pt was scheduled for her second dose of Moderna and called to say that she tested positive for COVID 11 days ago. She was not hospitalized and reports very minor symptoms such as cough.
No adverse event; injected the vaccine to a patient 2 days beyond expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (injected the vaccine to a patient 2 days beyond expiration date) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 045H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 14-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 14-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (injected the vaccine to a patient 2 days beyond expiration date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (injected the vaccine to a patient 2 days beyond expiration date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (injected the vaccine to a patient 2 days beyond expiration date).    No concomitant medication was reported.  Date the vial initially stored in the refrigerator on 01-JUN-2023. Expiry date was reported as 12-JUN-2023. No treatment information was reported.